Tarceva Trial Shows Broad Survival; PGx for First-Line Status Poses Double-Edged Sword | GenomeWeb

A large, recently concluded clinical trial of Tarceva demonstrated improved survival for all patient groups, so will the drug's development partners Genentech, OSI Pharmaceuticals, and Roche Pharmaceuticals remain happy with the drug's second-line status and never couple it with a diagnostic that could make it a first-line contender?

In November 2004, the US Food and Drug Administration approved Tarceva, also known by its scientific name erlotinib, for patients with advanced non-small cell lung cancer who had received at least one regimen of chemotherapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.